Clinical Trial Update: A Phase 2a Study to Evaluate the Safety and Tolerability of GM-2505 in Patients With MDD [Phase 2]

View source ↗

Summary

A clinical trial update shows GM-2505 is in Phase 2a testing for major depressive disorder and is currently recruiting to evaluate safety and tolerability.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• GM-2505

Snippet

Sponsor: Gilgamesh Pharmaceuticals | Conditions: Major Depressive Disorder | Phase 2 | Status: RECRUITING